{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:16Z","timestamp":1787026996053,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the cost-effectiveness of combining camrelizumab with rivoceranib versus sorafenib as initial treatment options for advanced hepatocellular carcinoma (HCC) across different developmental regions in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Utilizing TreeAge Pro and data from the phase III randomized CARES-310 clinical trial, a model based on Markov state transitions was developed. Health state utility values were derived from the CARES-310 trial, and direct medical costs were obtained from relevant literature and local pricing data. The primary outcome measured was the incremental cost-effectiveness ratio (ICER), defined as the cost per additional quality-adjusted life year (QALY) gained per person. The ICERs were compared against the willingness-to-pay (WTP) thresholds of different regions in China, including low-income ($16,426.80), medium-income ($34,319.01), and high-income regions ($81,036.63). Sensitivity analyses were also conducted to assess the robustness and reliability of the model under various assumptions. A tornado diagram was used to illustrate the impact of parameter variations on the model\u2019s cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For base case analysis, QALYs per person for the cohort receiving sorafenib were 0.91, with a corresponding cost of $8,860.97. For the cohort receiving camrelizumab plus rivoceranib, the QALYs per person were 1.71, with a corresponding cost of $16,190.72. The camrelizumab plus rivoceranib treatment group exhibited an increase of 0.80 QALYs and an additional expenditure of $7,329.75. The calculated ICER was $9,150.75 per QALY, which is below the WTP thresholds for all regions in China. The camrelizumab plus rivoceranib regimen is regarded as highly cost-effective in medium-income areas of China, with a probability of 99.9%. In high-income regions, the probability reaches 100.0%. Even in low-income regions, this regimen is considered 95.6% cost-effective. Sensitivity analysis further verified that these findings were robust across various assumptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of camrelizumab and rivoceranib as a treatment strategy not only improves health outcomes but also represents a cost-effective option across different developmental regions in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1491404","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:38Z","timestamp":1733443838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhonghua","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34724","article-title":"Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis","volume":"154","author":"Jiang","year":"2024","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100982","article-title":"A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma","volume":"6","author":"Balcar","year":"2024","journal-title":"JHEP Reports: Innovation Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0402","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective","volume":"29","author":"Xie","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: A report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000683","article-title":"Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and\/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial","volume":"109","author":"Chen","year":"2023","journal-title":"Int J Surg (London England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23857","article-title":"Dynamic distribution, regional differences and convergence of health workforce allocation in township health centers in China","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vhri.2015.06.004","article-title":"Health technology assessment, international reference pricing, and budget control tools from China\u2019s perspective: what are the current developments and future considerations","volume":"9","author":"Koh","year":"2016","journal-title":"Value Health Reg Issues"},{"key":"B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13561-024-00526-2","article-title":"Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review","volume":"14","author":"Gong","year":"2024","journal-title":"Health Econ Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01343-5","article-title":"Cost-effectiveness analysis of camrelizumab plus rivoceranib versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma in the chinese health care system","volume":"44","author":"Lang","year":"2024","journal-title":"Clin Drug Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-024-01752-8","article-title":"Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China","volume":"46","author":"Wei","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1264417","article-title":"Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma","volume":"13","author":"Tseng","year":"2023","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01038-2","article-title":"Atezolizumab and bevacizumab targeted-therapy in advanced hepatocellular carcinoma: A systematic review of cost-effectiveness analyses","volume":"55","author":"Mohammadnezhad","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.006","article-title":"A practical guide to understanding cost-effectiveness analyses","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S470470","article-title":"Additional hepatic arterial infusion chemotherapy to sorafenib was cost-effective for hepatocellular carcinoma with major portal vein tumor thrombosis","volume":"11","author":"Chen","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.778505","article-title":"Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-018-0112-0","article-title":"Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China","volume":"16","author":"Qin","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002774","article-title":"Recommended 10-year follow-up strategy for small hepatocellular carcinoma after radiofrequency ablation: A cost-effectiveness evaluation","volume":"119","author":"Chen","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12110","article-title":"Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"40","author":"Hou","year":"2020","journal-title":"Cancer Commun (London England)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1491404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:40Z","timestamp":1733443840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1491404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":28,"alternative-id":["10.3389\/fonc.2024.1491404"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1491404","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"1491404"}}